157 related articles for article (PubMed ID: 10799837)
1. Staurosporine analogues - pharmacological toys or useful antitumour agents?
Gescher A
Crit Rev Oncol Hematol; 2000 May; 34(2):127-35. PubMed ID: 10799837
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
Courage C; Bradder SM; Jones T; Schultze-Mosgau MH; Gescher A
Int J Cancer; 1997 Nov; 73(5):763-8. PubMed ID: 9398059
[TBL] [Abstract][Full Text] [Related]
3. Analogs of staurosporine: potential anticancer drugs?
Gescher A
Gen Pharmacol; 1998 Nov; 31(5):721-8. PubMed ID: 9809468
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
Courage C; Budworth J; Gescher A
Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931
[TBL] [Abstract][Full Text] [Related]
5. Cellular relocalisation of protein kinase C-theta caused by staurosporine and some of its analogues.
Jones T; Courage C; Hubbard A; Gescher A
Biochem Pharmacol; 1997 May; 53(10):1413-8. PubMed ID: 9260867
[TBL] [Abstract][Full Text] [Related]
6. Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C.
Harkin ST; Cohen GM; Gescher A
Mol Pharmacol; 1998 Oct; 54(4):663-70. PubMed ID: 9765509
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells.
Courage C; Snowden R; Gescher A
Br J Cancer; 1996 Oct; 74(8):1199-205. PubMed ID: 8883405
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.
Akiyama T; Shimizu M; Okabe M; Tamaoki T; Akinaga S
Anticancer Drugs; 1999 Jan; 10(1):67-78. PubMed ID: 10194549
[TBL] [Abstract][Full Text] [Related]
9. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
[TBL] [Abstract][Full Text] [Related]
11. A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells.
Sharif TR; Sharif M
Int J Oncol; 1999 Feb; 14(2):327-35. PubMed ID: 9917510
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C inhibitors.
Swannie HC; Kaye SB
Curr Oncol Rep; 2002 Jan; 4(1):37-46. PubMed ID: 11734112
[TBL] [Abstract][Full Text] [Related]
13. UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily.
Mizuno K; Noda K; Ueda Y; Hanaki H; Saido TC; Ikuta T; Kuroki T; Tamaoki T; Hirai S; Osada S
FEBS Lett; 1995 Feb; 359(2-3):259-61. PubMed ID: 7867810
[TBL] [Abstract][Full Text] [Related]
14. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.
Utz I; Hofer S; Regenass U; Hilbe W; Thaler J; Grunicke H; Hofmann J
Int J Cancer; 1994 Apr; 57(1):104-10. PubMed ID: 7908658
[TBL] [Abstract][Full Text] [Related]
15. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.
Meyer T; Regenass U; Fabbro D; Alteri E; Rösel J; Müller M; Caravatti G; Matter A
Int J Cancer; 1989 May; 43(5):851-6. PubMed ID: 2714889
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation.
Beltran PJ; Fan D; Fidler IJ; O'Brian CA
Biochem Pharmacol; 1997 Jan; 53(2):245-7. PubMed ID: 9037258
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C targeting in antineoplastic treatment strategies.
Jarvis WD; Grant S
Invest New Drugs; 1999; 17(3):227-40. PubMed ID: 10665476
[TBL] [Abstract][Full Text] [Related]
18. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
Seynaeve CM; Kazanietz MG; Blumberg PM; Sausville EA; Worland PJ
Mol Pharmacol; 1994 Jun; 45(6):1207-14. PubMed ID: 8022414
[TBL] [Abstract][Full Text] [Related]
19. Staurosporine-related compounds, K252a and UCN-01, inhibit both cPKC and nPKC.
Mizuno K; Saido TC; Ohno S; Tamaoki T; Suzuki K
FEBS Lett; 1993 Sep; 330(2):114-6. PubMed ID: 8365480
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.
Fabbro D; Buchdunger E; Wood J; Mestan J; Hofmann F; Ferrari S; Mett H; O'Reilly T; Meyer T
Pharmacol Ther; 1999; 82(2-3):293-301. PubMed ID: 10454207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
